Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets
| KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets. In Czech Chemical Society Symposium Series in Chemické Listy. 2018. |
|
Other formats:
BibTeX
LaTeX
RIS
|
| Basic information | |
|---|---|
| Original name | Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets |
| Name in Czech | Epigenetická screening léku rezistentní na rituximab buněčnou linii odhalil možné terapeutické cíle |
| Authors | KOZLOVÁ, Veronika (203 Czech Republic, belonging to the institution), Aneta LEDEREROVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution). |
| Edition | Czech Chemical Society Symposium Series in Chemické Listy, 2018. |
| Other information | |
|---|---|
| Original language | English |
| Type of outcome | Conference abstract |
| Field of Study | 10606 Microbiology |
| Confidentiality degree | is not subject to a state or trade secret |
| RIV identification code | RIV/00216224:14740/18:00104992 |
| Organization unit | Central European Institute of Technology |
| Keywords in English | Aurora; CD20; CLL; monoclonal |
| Tags | rivok |
| Changed by | Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 26/3/2019 15:40. |
| Abstract |
|---|
| Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets, Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets. |
| Abstract (in Czech) |
|---|
| Epigenetická screening léku rezistentní na rituximab buněčnou linii odhalil možné terapeutické cíle, Epigenetická screening léku rezistentní na rituximab buněčnou linii odhalil možné terapeutické cíle. |
| Links | |
|---|---|
| LQ1601, research and development project | Name: CEITEC 2020 (Acronym: CEITEC2020) |
| Investor: Ministry of Education, Youth and Sports of the CR | |
| MUNI/A/0968/2017, interní kód MU | Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V) |
| Investor: Masaryk University, Category A | |
| NV15-33561A, research and development project | Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie |
PrintDisplayed: 28/8/2024 17:31